412 related articles for article (PubMed ID: 9841887)
21. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
22. Topoisomerase II-mediated alterations of K562 drug resistant sublines.
Zhou R; Wang Y; Gruber A; Larsson R; Castaños-Vèlez E; Liliemark E
Med Oncol; 1999 Sep; 16(3):191-8. PubMed ID: 10523799
[TBL] [Abstract][Full Text] [Related]
23. Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Bhosle J; Kiakos K; Porter AC; Wu J; Makris A; Hartley JA; Hochhauser D
Mol Cancer Ther; 2013 Dec; 12(12):2897-908. PubMed ID: 24092808
[TBL] [Abstract][Full Text] [Related]
24. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
[TBL] [Abstract][Full Text] [Related]
25. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
[TBL] [Abstract][Full Text] [Related]
26. Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.
Bau JT; Kurz EU
Biochem Pharmacol; 2014 Jun; 89(4):464-76. PubMed ID: 24695359
[TBL] [Abstract][Full Text] [Related]
27. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
[TBL] [Abstract][Full Text] [Related]
28. Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells.
Aoyama M; Grabowski DR; Isaacs RJ; Krivacic KA; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Blood; 1998 Oct; 92(8):2863-70. PubMed ID: 9763571
[TBL] [Abstract][Full Text] [Related]
29. The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.
Wang SJ; Peyrollier K; Bourguignon LY
Arch Otolaryngol Head Neck Surg; 2007 Mar; 133(3):281-8. PubMed ID: 17372087
[TBL] [Abstract][Full Text] [Related]
30. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
31. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
32. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
[TBL] [Abstract][Full Text] [Related]
33. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
[TBL] [Abstract][Full Text] [Related]
34. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.
Engel R; Valkov NI; Gump JL; Hazlehurst L; Dalton WS; Sullivan DM
Exp Cell Res; 2004 May; 295(2):421-31. PubMed ID: 15093741
[TBL] [Abstract][Full Text] [Related]
35. A unique paclitaxel-mediated modulation of the catalytic activity of topoisomerase IIalpha.
Dhawan V; Swaffar DS
Anticancer Drugs; 1999 Apr; 10(4):397-404. PubMed ID: 10378675
[TBL] [Abstract][Full Text] [Related]
36. DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac.
Wartlick F; Bopp A; Henninger C; Fritz G
Biochim Biophys Acta; 2013 Dec; 1833(12):3093-3103. PubMed ID: 23999236
[TBL] [Abstract][Full Text] [Related]
37. The effects of a Ca2+ chelator and heavy-metal-ion chelators upon Ca2+ oscillations and activation at fertilization in mouse eggs suggest a role for repetitive Ca2+ increases.
Lawrence Y; Ozil JP; Swann K
Biochem J; 1998 Oct; 335 ( Pt 2)(Pt 2):335-42. PubMed ID: 9761732
[TBL] [Abstract][Full Text] [Related]
38. Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.
Hirota H; Gosky D; Berger NA; Chatterjee S
Int J Oncol; 2002 Feb; 20(2):311-8. PubMed ID: 11788894
[TBL] [Abstract][Full Text] [Related]
39. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
40. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
